nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RET—autonomic nervous system—attention deficit hyperactivity disorder	0.0229	0.0382	CbGeAlD
Sorafenib—CDKL2—forebrain—attention deficit hyperactivity disorder	0.0176	0.0294	CbGeAlD
Sorafenib—CDKL3—cardiovascular system—attention deficit hyperactivity disorder	0.0163	0.0272	CbGeAlD
Sorafenib—MUSK—nervous system—attention deficit hyperactivity disorder	0.0117	0.0196	CbGeAlD
Sorafenib—CDKL2—nervous system—attention deficit hyperactivity disorder	0.00955	0.016	CbGeAlD
Sorafenib—CDKL2—central nervous system—attention deficit hyperactivity disorder	0.0092	0.0154	CbGeAlD
Sorafenib—MAPK15—nervous system—attention deficit hyperactivity disorder	0.0086	0.0144	CbGeAlD
Sorafenib—MAPK15—central nervous system—attention deficit hyperactivity disorder	0.00828	0.0138	CbGeAlD
Sorafenib—CDKL3—brain—attention deficit hyperactivity disorder	0.00798	0.0133	CbGeAlD
Sorafenib—CDKL2—brain—attention deficit hyperactivity disorder	0.0073	0.0122	CbGeAlD
Sorafenib—ZAK—cardiovascular system—attention deficit hyperactivity disorder	0.00675	0.0113	CbGeAlD
Sorafenib—HIPK3—cardiovascular system—attention deficit hyperactivity disorder	0.00661	0.011	CbGeAlD
Sorafenib—MAPK15—brain—attention deficit hyperactivity disorder	0.00657	0.011	CbGeAlD
Sorafenib—TIE1—cardiovascular system—attention deficit hyperactivity disorder	0.00618	0.0103	CbGeAlD
Sorafenib—FLT3—cardiovascular system—attention deficit hyperactivity disorder	0.00562	0.00939	CbGeAlD
Sorafenib—FLT4—cardiovascular system—attention deficit hyperactivity disorder	0.0051	0.00853	CbGeAlD
Sorafenib—MAPK11—nervous system—attention deficit hyperactivity disorder	0.0051	0.00852	CbGeAlD
Sorafenib—CDK7—nervous system—attention deficit hyperactivity disorder	0.00502	0.00839	CbGeAlD
Sorafenib—AURKC—nervous system—attention deficit hyperactivity disorder	0.00494	0.00826	CbGeAlD
Sorafenib—RALBP1—forebrain—attention deficit hyperactivity disorder	0.00494	0.00825	CbGeAlD
Sorafenib—MAPK11—central nervous system—attention deficit hyperactivity disorder	0.00491	0.00821	CbGeAlD
Sorafenib—CDK7—central nervous system—attention deficit hyperactivity disorder	0.00483	0.00807	CbGeAlD
Sorafenib—MAPK11—cerebellum—attention deficit hyperactivity disorder	0.0048	0.00802	CbGeAlD
Sorafenib—AURKC—central nervous system—attention deficit hyperactivity disorder	0.00476	0.00795	CbGeAlD
Sorafenib—CDK7—cerebellum—attention deficit hyperactivity disorder	0.00472	0.00789	CbGeAlD
Sorafenib—TAOK2—cerebellum—attention deficit hyperactivity disorder	0.00468	0.00783	CbGeAlD
Sorafenib—RAF1—forebrain—attention deficit hyperactivity disorder	0.00467	0.0078	CbGeAlD
Sorafenib—EPHB6—forebrain—attention deficit hyperactivity disorder	0.00464	0.00776	CbGeAlD
Sorafenib—BRAF—midbrain—attention deficit hyperactivity disorder	0.00463	0.00773	CbGeAlD
Sorafenib—MKNK2—cardiovascular system—attention deficit hyperactivity disorder	0.00462	0.00772	CbGeAlD
Sorafenib—EPHA6—nervous system—attention deficit hyperactivity disorder	0.00457	0.00765	CbGeAlD
Sorafenib—MKNK1—cardiovascular system—attention deficit hyperactivity disorder	0.00456	0.00763	CbGeAlD
Sorafenib—HIPK4—brain—attention deficit hyperactivity disorder	0.00442	0.00739	CbGeAlD
Sorafenib—EPHA6—central nervous system—attention deficit hyperactivity disorder	0.0044	0.00736	CbGeAlD
Sorafenib—PDGFRA—forebrain—attention deficit hyperactivity disorder	0.0044	0.00735	CbGeAlD
Sorafenib—ZAK—nervous system—attention deficit hyperactivity disorder	0.00434	0.00725	CbGeAlD
Sorafenib—ZAK—central nervous system—attention deficit hyperactivity disorder	0.00418	0.00698	CbGeAlD
Sorafenib—RALBP1—cardiovascular system—attention deficit hyperactivity disorder	0.00417	0.00697	CbGeAlD
Sorafenib—MAP3K19—nervous system—attention deficit hyperactivity disorder	0.00416	0.00695	CbGeAlD
Sorafenib—ZAK—cerebellum—attention deficit hyperactivity disorder	0.00408	0.00682	CbGeAlD
Sorafenib—MAP3K19—central nervous system—attention deficit hyperactivity disorder	0.004	0.00669	CbGeAlD
Sorafenib—HIPK3—cerebellum—attention deficit hyperactivity disorder	0.00399	0.00667	CbGeAlD
Sorafenib—FLT1—cardiovascular system—attention deficit hyperactivity disorder	0.00397	0.00663	CbGeAlD
Sorafenib—KDR—forebrain—attention deficit hyperactivity disorder	0.00397	0.00663	CbGeAlD
Sorafenib—TIE1—nervous system—attention deficit hyperactivity disorder	0.00397	0.00663	CbGeAlD
Sorafenib—RAF1—cardiovascular system—attention deficit hyperactivity disorder	0.00395	0.0066	CbGeAlD
Sorafenib—FGFR1—midbrain—attention deficit hyperactivity disorder	0.00393	0.00657	CbGeAlD
Sorafenib—MAPK11—brain—attention deficit hyperactivity disorder	0.0039	0.00652	CbGeAlD
Sorafenib—CSF1R—forebrain—attention deficit hyperactivity disorder	0.00387	0.00647	CbGeAlD
Sorafenib—CDK7—brain—attention deficit hyperactivity disorder	0.00384	0.00641	CbGeAlD
Sorafenib—TIE1—central nervous system—attention deficit hyperactivity disorder	0.00382	0.00638	CbGeAlD
Sorafenib—TAOK2—brain—attention deficit hyperactivity disorder	0.0038	0.00636	CbGeAlD
Sorafenib—AURKC—brain—attention deficit hyperactivity disorder	0.00378	0.00631	CbGeAlD
Sorafenib—STK10—cardiovascular system—attention deficit hyperactivity disorder	0.00376	0.00628	CbGeAlD
Sorafenib—TIE1—cerebellum—attention deficit hyperactivity disorder	0.00373	0.00624	CbGeAlD
Sorafenib—MAP3K7—midbrain—attention deficit hyperactivity disorder	0.00372	0.00622	CbGeAlD
Sorafenib—PDGFRA—cardiovascular system—attention deficit hyperactivity disorder	0.00372	0.00622	CbGeAlD
Sorafenib—MKNK2—midbrain—attention deficit hyperactivity disorder	0.00361	0.00603	CbGeAlD
Sorafenib—BRAF—cerebellum—attention deficit hyperactivity disorder	0.00358	0.00598	CbGeAlD
Sorafenib—MKNK1—midbrain—attention deficit hyperactivity disorder	0.00356	0.00596	CbGeAlD
Sorafenib—RET—midbrain—attention deficit hyperactivity disorder	0.00352	0.00588	CbGeAlD
Sorafenib—EPHA6—brain—attention deficit hyperactivity disorder	0.0035	0.00584	CbGeAlD
Sorafenib—EPHX2—cerebellum—attention deficit hyperactivity disorder	0.00342	0.00572	CbGeAlD
Sorafenib—FLT3—cerebellum—attention deficit hyperactivity disorder	0.0034	0.00568	CbGeAlD
Sorafenib—KDR—cardiovascular system—attention deficit hyperactivity disorder	0.00336	0.00561	CbGeAlD
Sorafenib—MAP2K5—cardiovascular system—attention deficit hyperactivity disorder	0.00336	0.00561	CbGeAlD
Sorafenib—ZAK—brain—attention deficit hyperactivity disorder	0.00331	0.00554	CbGeAlD
Sorafenib—CSF1R—cardiovascular system—attention deficit hyperactivity disorder	0.00327	0.00547	CbGeAlD
Sorafenib—RALBP1—midbrain—attention deficit hyperactivity disorder	0.00326	0.00545	CbGeAlD
Sorafenib—HIPK3—brain—attention deficit hyperactivity disorder	0.00324	0.00542	CbGeAlD
Sorafenib—MAP3K19—brain—attention deficit hyperactivity disorder	0.00318	0.00531	CbGeAlD
Sorafenib—FLT1—midbrain—attention deficit hyperactivity disorder	0.0031	0.00518	CbGeAlD
Sorafenib—RAF1—midbrain—attention deficit hyperactivity disorder	0.00308	0.00515	CbGeAlD
Sorafenib—EPHB6—midbrain—attention deficit hyperactivity disorder	0.00306	0.00512	CbGeAlD
Sorafenib—FGFR1—cerebellum—attention deficit hyperactivity disorder	0.00304	0.00509	CbGeAlD
Sorafenib—TIE1—brain—attention deficit hyperactivity disorder	0.00303	0.00507	CbGeAlD
Sorafenib—KIT—cardiovascular system—attention deficit hyperactivity disorder	0.00297	0.00497	CbGeAlD
Sorafenib—MKNK2—nervous system—attention deficit hyperactivity disorder	0.00297	0.00496	CbGeAlD
Sorafenib—MKNK1—nervous system—attention deficit hyperactivity disorder	0.00293	0.0049	CbGeAlD
Sorafenib—BRAF—brain—attention deficit hyperactivity disorder	0.00291	0.00486	CbGeAlD
Sorafenib—PDGFRB—cardiovascular system—attention deficit hyperactivity disorder	0.0029	0.00485	CbGeAlD
Sorafenib—HTR2C—forebrain—attention deficit hyperactivity disorder	0.0029	0.00484	CbGeAlD
Sorafenib—RET—nervous system—attention deficit hyperactivity disorder	0.00289	0.00484	CbGeAlD
Sorafenib—MAP3K7—cerebellum—attention deficit hyperactivity disorder	0.00288	0.00481	CbGeAlD
Sorafenib—MKNK2—central nervous system—attention deficit hyperactivity disorder	0.00286	0.00477	CbGeAlD
Sorafenib—MKNK1—central nervous system—attention deficit hyperactivity disorder	0.00282	0.00471	CbGeAlD
Sorafenib—MKNK2—cerebellum—attention deficit hyperactivity disorder	0.00279	0.00467	CbGeAlD
Sorafenib—RET—central nervous system—attention deficit hyperactivity disorder	0.00279	0.00466	CbGeAlD
Sorafenib—EPHX2—brain—attention deficit hyperactivity disorder	0.00278	0.00464	CbGeAlD
Sorafenib—MKNK1—cerebellum—attention deficit hyperactivity disorder	0.00276	0.00461	CbGeAlD
Sorafenib—ABCC4—forebrain—attention deficit hyperactivity disorder	0.00273	0.00457	CbGeAlD
Sorafenib—RET—cerebellum—attention deficit hyperactivity disorder	0.00272	0.00455	CbGeAlD
Sorafenib—HTR2B—forebrain—attention deficit hyperactivity disorder	0.00272	0.00455	CbGeAlD
Sorafenib—RALBP1—nervous system—attention deficit hyperactivity disorder	0.00268	0.00448	CbGeAlD
Sorafenib—KDR—midbrain—attention deficit hyperactivity disorder	0.00262	0.00438	CbGeAlD
Sorafenib—MAP2K5—midbrain—attention deficit hyperactivity disorder	0.00262	0.00438	CbGeAlD
Sorafenib—RALBP1—central nervous system—attention deficit hyperactivity disorder	0.00258	0.00431	CbGeAlD
Sorafenib—CSF1R—midbrain—attention deficit hyperactivity disorder	0.00256	0.00427	CbGeAlD
Sorafenib—FLT1—nervous system—attention deficit hyperactivity disorder	0.00255	0.00426	CbGeAlD
Sorafenib—RAF1—nervous system—attention deficit hyperactivity disorder	0.00253	0.00423	CbGeAlD
Sorafenib—RALBP1—cerebellum—attention deficit hyperactivity disorder	0.00252	0.00421	CbGeAlD
Sorafenib—EPHB6—nervous system—attention deficit hyperactivity disorder	0.00252	0.00421	CbGeAlD
Sorafenib—FLT4—brain—attention deficit hyperactivity disorder	0.00251	0.00419	CbGeAlD
Sorafenib—FGFR1—brain—attention deficit hyperactivity disorder	0.00247	0.00413	CbGeAlD
Sorafenib—FLT1—central nervous system—attention deficit hyperactivity disorder	0.00245	0.0041	CbGeAlD
Sorafenib—RAF1—central nervous system—attention deficit hyperactivity disorder	0.00244	0.00408	CbGeAlD
Sorafenib—EPHB6—central nervous system—attention deficit hyperactivity disorder	0.00243	0.00405	CbGeAlD
Sorafenib—STK10—nervous system—attention deficit hyperactivity disorder	0.00241	0.00403	CbGeAlD
Sorafenib—FLT1—cerebellum—attention deficit hyperactivity disorder	0.0024	0.00401	CbGeAlD
Sorafenib—PDGFRA—nervous system—attention deficit hyperactivity disorder	0.00239	0.00399	CbGeAlD
Sorafenib—RAF1—cerebellum—attention deficit hyperactivity disorder	0.00238	0.00398	CbGeAlD
Sorafenib—EPHB6—cerebellum—attention deficit hyperactivity disorder	0.00237	0.00396	CbGeAlD
Sorafenib—MAP3K7—brain—attention deficit hyperactivity disorder	0.00234	0.00391	CbGeAlD
Sorafenib—STK10—central nervous system—attention deficit hyperactivity disorder	0.00232	0.00388	CbGeAlD
Sorafenib—KIT—midbrain—attention deficit hyperactivity disorder	0.00232	0.00388	CbGeAlD
Sorafenib—HTR2B—cardiovascular system—attention deficit hyperactivity disorder	0.0023	0.00384	CbGeAlD
Sorafenib—PDGFRA—central nervous system—attention deficit hyperactivity disorder	0.0023	0.00384	CbGeAlD
Sorafenib—STK10—cerebellum—attention deficit hyperactivity disorder	0.00227	0.00379	CbGeAlD
Sorafenib—PDGFRB—midbrain—attention deficit hyperactivity disorder	0.00227	0.00379	CbGeAlD
Sorafenib—MKNK2—brain—attention deficit hyperactivity disorder	0.00227	0.00379	CbGeAlD
Sorafenib—PDGFRA—cerebellum—attention deficit hyperactivity disorder	0.00225	0.00376	CbGeAlD
Sorafenib—MKNK1—brain—attention deficit hyperactivity disorder	0.00224	0.00374	CbGeAlD
Sorafenib—RET—brain—attention deficit hyperactivity disorder	0.00221	0.0037	CbGeAlD
Sorafenib—MAP2K5—nervous system—attention deficit hyperactivity disorder	0.00215	0.0036	CbGeAlD
Sorafenib—KDR—nervous system—attention deficit hyperactivity disorder	0.00215	0.0036	CbGeAlD
Sorafenib—CSF1R—nervous system—attention deficit hyperactivity disorder	0.0021	0.00351	CbGeAlD
Sorafenib—KDR—central nervous system—attention deficit hyperactivity disorder	0.00207	0.00347	CbGeAlD
Sorafenib—MAP2K5—central nervous system—attention deficit hyperactivity disorder	0.00207	0.00347	CbGeAlD
Sorafenib—RALBP1—brain—attention deficit hyperactivity disorder	0.00205	0.00342	CbGeAlD
Sorafenib—MAP2K5—cerebellum—attention deficit hyperactivity disorder	0.00203	0.00339	CbGeAlD
Sorafenib—KDR—cerebellum—attention deficit hyperactivity disorder	0.00203	0.00339	CbGeAlD
Sorafenib—CSF1R—central nervous system—attention deficit hyperactivity disorder	0.00202	0.00338	CbGeAlD
Sorafenib—CSF1R—cerebellum—attention deficit hyperactivity disorder	0.00198	0.00331	CbGeAlD
Sorafenib—FLT1—brain—attention deficit hyperactivity disorder	0.00195	0.00326	CbGeAlD
Sorafenib—RAF1—brain—attention deficit hyperactivity disorder	0.00194	0.00324	CbGeAlD
Sorafenib—EPHB6—brain—attention deficit hyperactivity disorder	0.00193	0.00322	CbGeAlD
Sorafenib—HTR2C—midbrain—attention deficit hyperactivity disorder	0.00191	0.0032	CbGeAlD
Sorafenib—KIT—nervous system—attention deficit hyperactivity disorder	0.00191	0.00319	CbGeAlD
Sorafenib—PDGFRB—nervous system—attention deficit hyperactivity disorder	0.00186	0.00312	CbGeAlD
Sorafenib—STK10—brain—attention deficit hyperactivity disorder	0.00184	0.00308	CbGeAlD
Sorafenib—KIT—central nervous system—attention deficit hyperactivity disorder	0.00184	0.00307	CbGeAlD
Sorafenib—PDGFRA—brain—attention deficit hyperactivity disorder	0.00183	0.00305	CbGeAlD
Sorafenib—KIT—cerebellum—attention deficit hyperactivity disorder	0.0018	0.003	CbGeAlD
Sorafenib—PDGFRB—central nervous system—attention deficit hyperactivity disorder	0.0018	0.003	CbGeAlD
Sorafenib—PDGFRB—cerebellum—attention deficit hyperactivity disorder	0.00175	0.00293	CbGeAlD
Sorafenib—KDR—brain—attention deficit hyperactivity disorder	0.00165	0.00275	CbGeAlD
Sorafenib—MAP2K5—brain—attention deficit hyperactivity disorder	0.00165	0.00275	CbGeAlD
Sorafenib—CSF1R—brain—attention deficit hyperactivity disorder	0.00161	0.00269	CbGeAlD
Sorafenib—HTR2C—nervous system—attention deficit hyperactivity disorder	0.00157	0.00263	CbGeAlD
Sorafenib—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.00151	0.00253	CbGeAlD
Sorafenib—CYP2B6—cardiovascular system—attention deficit hyperactivity disorder	0.00151	0.00252	CbGeAlD
Sorafenib—CYP2C9—cardiovascular system—attention deficit hyperactivity disorder	0.00149	0.00249	CbGeAlD
Sorafenib—ABCC4—nervous system—attention deficit hyperactivity disorder	0.00148	0.00248	CbGeAlD
Sorafenib—HTR2B—nervous system—attention deficit hyperactivity disorder	0.00148	0.00247	CbGeAlD
Sorafenib—KIT—brain—attention deficit hyperactivity disorder	0.00146	0.00244	CbGeAlD
Sorafenib—ABCC4—central nervous system—attention deficit hyperactivity disorder	0.00143	0.00239	CbGeAlD
Sorafenib—PDGFRB—brain—attention deficit hyperactivity disorder	0.00143	0.00238	CbGeAlD
Sorafenib—HTR2B—central nervous system—attention deficit hyperactivity disorder	0.00142	0.00238	CbGeAlD
Sorafenib—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00132	0.00221	CbGeAlD
Sorafenib—ABCG2—midbrain—attention deficit hyperactivity disorder	0.00127	0.00213	CbGeAlD
Sorafenib—HTR2C—brain—attention deficit hyperactivity disorder	0.0012	0.00201	CbGeAlD
Sorafenib—ABCC4—brain—attention deficit hyperactivity disorder	0.00113	0.0019	CbGeAlD
Sorafenib—HTR2B—brain—attention deficit hyperactivity disorder	0.00113	0.00189	CbGeAlD
Sorafenib—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.000986	0.00165	CbGeAlD
Sorafenib—CYP2B6—nervous system—attention deficit hyperactivity disorder	0.000967	0.00162	CbGeAlD
Sorafenib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000952	0.00159	CbGeAlD
Sorafenib—CYP2B6—central nervous system—attention deficit hyperactivity disorder	0.000931	0.00156	CbGeAlD
Sorafenib—CYP2C8—brain—attention deficit hyperactivity disorder	0.000824	0.00138	CbGeAlD
Sorafenib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000805	0.00135	CbGeAlD
Sorafenib—ABCG2—brain—attention deficit hyperactivity disorder	0.000801	0.00134	CbGeAlD
Sorafenib—CYP2B6—brain—attention deficit hyperactivity disorder	0.000739	0.00124	CbGeAlD
Sorafenib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00073	0.00122	CbGeAlD
Sorafenib—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000718	0.0012	CbGeAlD
Sorafenib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.000703	0.00117	CbGeAlD
Sorafenib—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000692	0.00116	CbGeAlD
Sorafenib—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000676	0.00113	CbGeAlD
Sorafenib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000629	0.00105	CbGeAlD
Sorafenib—CYP2D6—brain—attention deficit hyperactivity disorder	0.000549	0.000918	CbGeAlD
Sorafenib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000517	0.000864	CbGeAlD
Sorafenib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.000498	0.000832	CbGeAlD
Sorafenib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000486	0.000813	CbGeAlD
Sorafenib—ABCB1—brain—attention deficit hyperactivity disorder	0.000395	0.00066	CbGeAlD
Sorafenib—KIT—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000109	0.000271	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000109	0.00027	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000108	0.000269	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000108	0.000269	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000108	0.000269	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000108	0.000268	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000107	0.000266	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000107	0.000266	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000106	0.000265	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000106	0.000264	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000106	0.000263	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000106	0.000263	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000105	0.000262	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000104	0.00026	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000104	0.000259	CbGpPWpGaD
Sorafenib—EPHX2—Metabolism—EP300—attention deficit hyperactivity disorder	0.000104	0.000258	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000103	0.000257	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000103	0.000256	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000101	0.000252	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000101	0.000252	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000101	0.000252	CbGpPWpGaD
Sorafenib—MKNK1—Disease—EP300—attention deficit hyperactivity disorder	0.000101	0.000251	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.0001	0.00025	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.0001	0.00025	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—TPH2—attention deficit hyperactivity disorder	9.93e-05	0.000247	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.93e-05	0.000247	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	9.86e-05	0.000245	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	9.83e-05	0.000245	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.82e-05	0.000244	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.79e-05	0.000244	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.79e-05	0.000244	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—DPYD—attention deficit hyperactivity disorder	9.77e-05	0.000243	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	9.72e-05	0.000242	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—EP300—attention deficit hyperactivity disorder	9.67e-05	0.000241	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.62e-05	0.000239	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.62e-05	0.000239	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.59e-05	0.000239	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.57e-05	0.000238	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.5e-05	0.000237	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.5e-05	0.000237	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9.45e-05	0.000235	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.44e-05	0.000235	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.44e-05	0.000235	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.4e-05	0.000234	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—EP300—attention deficit hyperactivity disorder	9.37e-05	0.000233	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.29e-05	0.000231	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.27e-05	0.000231	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	9.26e-05	0.000231	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.17e-05	0.000228	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.13e-05	0.000227	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	9.11e-05	0.000227	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.09e-05	0.000226	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	9.02e-05	0.000224	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.01e-05	0.000224	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.99e-05	0.000224	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.99e-05	0.000224	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	8.99e-05	0.000224	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.85e-05	0.00022	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.85e-05	0.00022	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.84e-05	0.00022	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—EP300—attention deficit hyperactivity disorder	8.76e-05	0.000218	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.72e-05	0.000217	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.72e-05	0.000217	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.67e-05	0.000216	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.62e-05	0.000215	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.53e-05	0.000212	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.53e-05	0.000212	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.4e-05	0.000209	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.38e-05	0.000209	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.35e-05	0.000208	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.28e-05	0.000206	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.26e-05	0.000206	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.26e-05	0.000206	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	8.24e-05	0.000205	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.22e-05	0.000205	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.2e-05	0.000204	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	8.2e-05	0.000204	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.16e-05	0.000203	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.1e-05	0.000202	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	8.04e-05	0.0002	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.01e-05	0.000199	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.99e-05	0.000199	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.98e-05	0.000199	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.96e-05	0.000198	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.94e-05	0.000198	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.85e-05	0.000195	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.82e-05	0.000195	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.73e-05	0.000192	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.68e-05	0.000191	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.63e-05	0.00019	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.58e-05	0.000189	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	7.57e-05	0.000188	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.56e-05	0.000188	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.55e-05	0.000188	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—EP300—attention deficit hyperactivity disorder	7.51e-05	0.000187	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.44e-05	0.000185	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.44e-05	0.000185	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.4e-05	0.000184	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—EP300—attention deficit hyperactivity disorder	7.36e-05	0.000183	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—TPH2—attention deficit hyperactivity disorder	7.35e-05	0.000183	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.35e-05	0.000183	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.33e-05	0.000183	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.31e-05	0.000182	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—DPYD—attention deficit hyperactivity disorder	7.23e-05	0.00018	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.22e-05	0.00018	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.2e-05	0.000179	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	7.18e-05	0.000179	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.18e-05	0.000179	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—COMT—attention deficit hyperactivity disorder	7.16e-05	0.000178	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—COMT—attention deficit hyperactivity disorder	7.16e-05	0.000178	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.13e-05	0.000178	CbGpPWpGaD
Sorafenib—CDK7—Disease—EP300—attention deficit hyperactivity disorder	7.11e-05	0.000177	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	7.11e-05	0.000177	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—MAOA—attention deficit hyperactivity disorder	7.11e-05	0.000177	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.07e-05	0.000176	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	7.06e-05	0.000176	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	6.89e-05	0.000172	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.89e-05	0.000171	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.87e-05	0.000171	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.81e-05	0.00017	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.73e-05	0.000167	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.72e-05	0.000167	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.63e-05	0.000165	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—EP300—attention deficit hyperactivity disorder	6.63e-05	0.000165	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.57e-05	0.000163	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.42e-05	0.00016	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.37e-05	0.000158	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.31e-05	0.000157	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.27e-05	0.000156	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.23e-05	0.000155	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	6.22e-05	0.000155	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.22e-05	0.000155	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.2e-05	0.000154	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.2e-05	0.000154	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	6.12e-05	0.000152	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	6.07e-05	0.000151	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	6.03e-05	0.00015	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	6.02e-05	0.00015	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	5.98e-05	0.000149	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.88e-05	0.000146	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.87e-05	0.000146	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.87e-05	0.000146	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.81e-05	0.000145	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.74e-05	0.000143	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.69e-05	0.000142	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—EP300—attention deficit hyperactivity disorder	5.63e-05	0.00014	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.59e-05	0.000139	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	5.55e-05	0.000138	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.55e-05	0.000138	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.47e-05	0.000136	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	5.46e-05	0.000136	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	5.42e-05	0.000135	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.42e-05	0.000135	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	5.33e-05	0.000133	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.29e-05	0.000132	CbGpPWpGaD
Sorafenib—BRAF—Disease—EP300—attention deficit hyperactivity disorder	5.15e-05	0.000128	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.11e-05	0.000127	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	5.11e-05	0.000127	CbGpPWpGaD
Sorafenib—KIT—Immune System—EP300—attention deficit hyperactivity disorder	5.08e-05	0.000126	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EP300—attention deficit hyperactivity disorder	5.08e-05	0.000126	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.08e-05	0.000126	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.06e-05	0.000126	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	5.06e-05	0.000126	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.04e-05	0.000126	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	5.02e-05	0.000125	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	4.98e-05	0.000124	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.97e-05	0.000124	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.96e-05	0.000123	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.84e-05	0.00012	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EP300—attention deficit hyperactivity disorder	4.82e-05	0.00012	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EP300—attention deficit hyperactivity disorder	4.81e-05	0.00012	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.73e-05	0.000118	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.71e-05	0.000117	CbGpPWpGaD
Sorafenib—KIT—Disease—EP300—attention deficit hyperactivity disorder	4.69e-05	0.000117	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.67e-05	0.000116	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.63e-05	0.000115	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—COMT—attention deficit hyperactivity disorder	4.45e-05	0.000111	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EP300—attention deficit hyperactivity disorder	4.45e-05	0.000111	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EP300—attention deficit hyperactivity disorder	4.44e-05	0.000111	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.44e-05	0.00011	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MAOA—attention deficit hyperactivity disorder	4.42e-05	0.00011	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	4.35e-05	0.000108	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.35e-05	0.000108	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EP300—attention deficit hyperactivity disorder	4.33e-05	0.000108	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.33e-05	0.000108	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	4.33e-05	0.000108	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.33e-05	0.000108	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	4.32e-05	0.000108	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	4.26e-05	0.000106	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.24e-05	0.000105	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.23e-05	0.000105	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.12e-05	0.000103	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.08e-05	0.000102	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.07e-05	0.000101	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.05e-05	0.000101	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EP300—attention deficit hyperactivity disorder	4e-05	9.96e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.96e-05	9.85e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.89e-05	9.67e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EP300—attention deficit hyperactivity disorder	3.86e-05	9.61e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.85e-05	9.59e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	3.77e-05	9.38e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	3.74e-05	9.31e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.64e-05	9.07e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.63e-05	9.03e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.61e-05	8.98e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EP300—attention deficit hyperactivity disorder	3.56e-05	8.87e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.46e-05	8.61e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	3.36e-05	8.37e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	3.34e-05	8.31e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	3.34e-05	8.31e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.34e-05	8.31e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.29e-05	8.2e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	3.28e-05	8.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.28e-05	8.18e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.28e-05	8.18e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	3.28e-05	8.17e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	3.26e-05	8.12e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.24e-05	8.06e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.12e-05	7.76e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.11e-05	7.74e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	3.09e-05	7.7e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	3.07e-05	7.65e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—attention deficit hyperactivity disorder	3.07e-05	7.64e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—attention deficit hyperactivity disorder	3.07e-05	7.64e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	3.07e-05	7.63e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.05e-05	7.6e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	3.05e-05	7.58e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.95e-05	7.35e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.8e-05	6.97e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.67e-05	6.65e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.67e-05	6.64e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	2.62e-05	6.52e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	2.6e-05	6.48e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	2.6e-05	6.48e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	2.58e-05	6.43e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.54e-05	6.32e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.52e-05	6.28e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.5e-05	6.21e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.15e-05	5.36e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	2.02e-05	5.04e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	2.01e-05	5e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—attention deficit hyperactivity disorder	1.91e-05	4.75e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	1.87e-05	4.64e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	1.62e-05	4.02e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	1.44e-05	3.59e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	1.41e-05	3.5e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.33e-05	3.3e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	1.32e-05	3.27e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	1.12e-05	2.8e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	8.67e-06	2.16e-05	CbGpPWpGaD
